Home » Market News » DirectorsTalk Highlights » Evgen Pharma PLC SFX-01 data published in Peer Reviewed Journal
Evgen Pharma Plc

Evgen Pharma PLC SFX-01 data published in Peer Reviewed Journal

Evgen Pharma PLC (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce the publication in a peer reviewed scientific journal of its lead product, SFX-01 and its protective effects against osteoarthritis.

The paper, “Stable sulforaphane protects against gait anomalies and modifies bone microarchitecture in the spontaneous STR/Ort model of osteoarthritis”, has been published in the journal Bone and describes the work undertaken by researchers to see how SFX-01 modifies gait, bone architecture and slows or reverses articular cartilage destruction in a spontaneous osteoarthritis model in mice.

This follows the news in the AGM Statement announced on 26 July 2017, that Evgen, together with the RVC, University of London, has secured grant funding to continue its collaboration to build on this, now published, preclinical data demonstrating the potential of SFX-01 as a treatment for osteoarthritis.

 

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.